BKYI — BIO-key International, Inc.

Summary of BIO-key International's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• 2025 Revenue: Decreased by 12% to $6.1 million from $6.9 million in 2024.
• Q4 2025 Revenue: License Fee revenue fell by 26%, while Hardware revenue surged by 85% and Service revenue decreased by 10%.
• Gross Margin: 77.5% for 2025, down from 81.4% in 2024, but improved to 91% for License Fee revenue.
• Net Loss: Increased to $4.6 million ($0.69 per share) for 2025, compared to $4.3 million ($2.09 per share) in 2024. Q4 net loss was $1.7 million ($0.19 per share), up from $1.4 million ($0.46 per share) in 2024.
• Cash Position: Ended 2025 with $2.7 million in cash, up from $438,000 in 2024. Book value increased to $7.6 million from $3.8 million.

2. Strategic Updates and Business Highlights

• Transitioned to selling only BIO-key-branded solutions in EMEA, expected to enhance gross margins and growth prospects.
• Launched the Defense & Intelligence Cybersecurity Initiative in 2025, with notable contract wins in defense and financial sectors.
• Introduced the EcoID III fingerprint scanner, aimed at highly regulated industries.
• Significant focus on R&D, with a major update to the PortalGuard Identity platform (Version 7.0) expected in Q2 2026.

3. Forward Guidance and Outlook

• Anticipates Q1 2026 revenue of approximately $2.2 million, representing a 37% increase over Q1 2025.
• Expects substantial improvement in Q1 2026 bottom line performance, aiming for breakeven and profitability in 2026.
• The enterprise authentication market is projected to grow significantly, with increasing demand for secure access solutions.

4. Bad News, Challenges, or Points of Concern

• 2025 revenue performance was disappointing, primarily due to timing issues with a significant contract renewal that impacted recognized revenue.
• The transition in the EMEA region took longer than expected, affecting revenue growth.
• The company faces competitive pressures in the authentication market, particularly from larger competitors.
• Potential risk of a reverse stock split if the share price does not exceed $1 for 10 consecutive days before early May 2026.

5. Notable Q&A Insights

• Clarified that the $1 million contract renewal with a foreign bank represents a 30% increase and is a continuation of a previous two-year contract.
• Emphasized strong optimism for 2026, citing urgency from customers in regulated industries for enhanced security solutions.
• Discussed ongoing partnerships, particularly with TD Synnex, which are expected to drive growth in the public sector.
• Addressed concerns about expenses, indicating stability and a focus on cost management while investing in R&D.
• Confirmed that the company is in a strong position to achieve breakeven and profitability, with a focus on subscription-based revenue and multi-year contracts.

Overall, BIO-key International is navigating a challenging financial landscape but is optimistic about future growth driven by strategic initiatives and market demand for enhanced security solutions.